Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
Titel:
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
Auteur:
Eder, Joseph P. Ryan, David P. Appleman, Leonard Zhu, Andrew X. Puchalski, Thomas He, Xiaoying Sonnichsen, Daryl S. Cooper, Michael Wright, John Clark, Jeffrey W. Supko, Jeffrey G.